by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka BloodAdv Volume 2(10):1066-1075 May 22, 2018 © 2018 by The American Society of Hematology

Hideki Yoshioka et al. Blood Adv 2018;2:1066-1075 © 2018 by The American Society of Hematology

Flowchart of the study selection process. Hideki Yoshioka et al. Blood Adv 2018;2:1066-1075 © 2018 by The American Society of Hematology

Model-estimated relationships between PT ratio and event risks in FXa inhibitors estimated by a MBMA. (A) Ischemic stroke/SE. Model-estimated relationships between PT ratio and event risks in FXa inhibitors estimated by a MBMA. (A) Ischemic stroke/SE. (B) Major bleeding. The solid curves and shaded areas represent the median estimates and 95% CIs, respectively. The symbols indicate observations in clinical trials vs the population means of the time-average of the PT ratio. The horizontal lines on the symbols represent the range between the trough and peak of the PT ratio as the population mean, and the vertical lines represent the 95% CI of the observations. Hideki Yoshioka et al. Blood Adv 2018;2:1066-1075 © 2018 by The American Society of Hematology

Event rates of ischemic stroke/SE and major bleeding simulated for various dose regimens of each FXa inhibitor. Event rates of ischemic stroke/SE and major bleeding simulated for various dose regimens of each FXa inhibitor. Left and right boxes for each daily dose represent once-daily and twice-daily administrations, respectively (ie, the box on the right side of X mg represents predictions when X/2 mg is administered twice a day). The horizontal dashed lines represent median predictions for the current dose regimens of each agent marked with downward arrows. The bars represent 95% CIs of the total incidence, derived from 1000 iterations. Hideki Yoshioka et al. Blood Adv 2018;2:1066-1075 © 2018 by The American Society of Hematology

Mortality rates from ischemic stroke/SE and major bleeding simulated for various dose regimens of each FXa inhibitor. Mortality rates from ischemic stroke/SE and major bleeding simulated for various dose regimens of each FXa inhibitor. The figure is created in the same format as in Figure 3. Hideki Yoshioka et al. Blood Adv 2018;2:1066-1075 © 2018 by The American Society of Hematology